Pyruvate Modulation of Inflammatory Agents for Pulmonary Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary diseases often result in imbalanced immune responses due to abnormal levels of inflammatory agents, leading to increased infections and tissue damage, as existing medications can either suppress the immune system or fail to adequately regulate inflammatory cytokines.
Innovation Solution
The use of pyruvates and pyruvate precursors to up-regulate or down-regulate inflammatory agents such as cytokines, transforming growth factor-β, elastase, and white blood cells, thereby balancing the immune response and addressing the imbalance caused by excessive or deficient inflammatory cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat pulmonary diseases, then immune suppression or failure to regulate inflammatory cytokines occurs, but immune system balance is disrupted leading to increased infections and tissue damage
Solution Approach 1:
The patent changes the parameter of inflammatory cytokine levels by administering pyruvate, which modulates the production and activity of inflammatory agents. This shifts the immune response from an imbalanced state (either suppressed or excessively inflammatory) to a balanced state that fights infections while preventing tissue damage
Solution Approach 2:
Pyruvate acts as an intermediary substance that mediates between the immune system's need to fight infections and the need to prevent tissue damage. It regulates the levels and activity of inflammatory cytokines, serving as a bridge that balances opposing immune responses
2Reliability
If inflammatory agents are up-regulated to fight infections, then immune response is enhanced, but tissue damage increases due to excessive inflammation
Solution Approach 1:
The patent implements a feedback mechanism where pyruvate administration monitors and adjusts inflammatory cytokine levels. When inflammation becomes excessive and threatens tissue damage, pyruvate modulates the response to reduce inflammation while maintaining infection-fighting capability, creating a self-regulating system
3Object-affected harmful factors
If immune system is suppressed to reduce inflammation, then tissue damage is reduced, but infection risk increases due to weakened immune response
Solution Approach 1:
The patent applies dynamics by making the immune response flexible and adaptable through pyruvate administration. The system can dynamically adjust between anti-inflammatory and pro-inflammatory states based on the balance of inflammatory cytokines, rather than being fixed in either suppression or activation
Data Source
AI summary
The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine.